Sigma Planning Corp Buys New Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Sigma Planning Corp bought a new stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 21,275 shares of the biopharmaceutical company's stock, valued at approximately $516,000.

Other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC boosted its position in shares of Catalyst Pharmaceuticals by 26.2% during the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 579 shares during the period. Summit Investment Advisors Inc. boosted its position in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. Summit Investment Advisors Inc. now owns 11,696 shares of the biopharmaceutical company's stock worth $244,000 after buying an additional 580 shares during the period. Bank of Montreal Can boosted its position in shares of Catalyst Pharmaceuticals by 6.2% during the fourth quarter. Bank of Montreal Can now owns 14,879 shares of the biopharmaceutical company's stock worth $311,000 after buying an additional 875 shares during the period. Illinois Municipal Retirement Fund boosted its position in shares of Catalyst Pharmaceuticals by 1.6% during the first quarter. Illinois Municipal Retirement Fund now owns 60,638 shares of the biopharmaceutical company's stock worth $1,470,000 after buying an additional 929 shares during the period. Finally, PDT Partners LLC boosted its position in shares of Catalyst Pharmaceuticals by 5.2% during the fourth quarter. PDT Partners LLC now owns 20,664 shares of the biopharmaceutical company's stock worth $431,000 after buying an additional 1,030 shares during the period. 79.22% of the stock is owned by institutional investors.

Catalyst Pharmaceuticals Stock Performance

Shares of NASDAQ CPRX traded down $0.42 during mid-day trading on Friday, reaching $21.03. The company had a trading volume of 1,230,712 shares, compared to its average volume of 1,146,224. Catalyst Pharmaceuticals, Inc. has a twelve month low of $15.34 and a twelve month high of $26.58. The stock has a market capitalization of $2.57 billion, a PE ratio of 13.39, a price-to-earnings-growth ratio of 0.86 and a beta of 0.66. The stock's 50 day moving average is $23.23 and its 200-day moving average is $22.89.

Insiders Place Their Bets

In related news, insider Gary Ingenito sold 200,000 shares of the company's stock in a transaction on Tuesday, May 13th. The shares were sold at an average price of $23.68, for a total value of $4,736,000.00. Following the completion of the sale, the insider directly owned 68,873 shares in the company, valued at approximately $1,630,912.64. This represents a 74.38% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Preethi Sundaram sold 2,324 shares of the company's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $26.41, for a total transaction of $61,376.84. Following the completion of the sale, the insider owned 42,681 shares of the company's stock, valued at $1,127,205.21. This represents a 5.16% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 247,924 shares of company stock worth $5,879,369 over the last ninety days. 10.40% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Separately, Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a "strong-buy" rating in a research report on Thursday, June 5th. Six research analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, Catalyst Pharmaceuticals has an average rating of "Buy" and a consensus price target of $32.83.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.